Atara biotherapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of inducement awards to charlene banard, its new executive vice president, chief technical officer. the compensation committee of atara's board of directors granted ms. banard 155,350 restricted stock units of at
ATRA Ratings Summary
ATRA Quant Ranking